['chronic hepatitis c', 'hepatitis c virus', 'hcv']
['abt-493/abt-530']

        Inclusion Criteria:

          -  Male or female, at least 18 years of age at time of screening.

          -  Screening laboratory result indicating hepatitis C virus (HCV) genotype 1 (GT1)
             infection.

          -  Chronic HCV infection.

          -  Subject must be HCV treatment-naïve (i.e., patient has never received a single dose of
             any approved or investigational regimen) or treatment-experienced (has failed prior
             interferon [IFN] or pegylated IFN (pegIFN) with or without ribivarin (RBV), or
             sofosbuvir (SOF) plus RBV with or without pegIFN therapy).

          -  Subjects must be non-cirrhotic.

        Additional Inclusion Criteria for HCV GT1/human immununovirus type 1 (HIV-1) co-infected
        patients:

          -  HIV-1 antiretroviral treatment (ART) naïve with CD4 ≥ 500 cells/mm3 (or CD4+ % ≥ 29%)
             at Screening and plasma HIV-1 RNA <1,000 copies/mL at Screening and at least once
             during the 12 months prior to Screening.

        OR

          -  On a stable, qualifying HIV-1 ART regimen for at least 8 weeks prior to screening,
             with CD4 ≥ 200 cells/mm3 (or CD4+ % ≥14%) at Screening and plasma HIV-1 RNA < LLOQ at
             Screening and at least once during the 12 months prior to Screening.

        Exclusion Criteria:

          -  History of severe, life-threatening or other significant sensitivity to any excipients
             of the study drugs.

          -  Female who is pregnant, planning to become pregnant during the study or breastfeeding;
             or male whose partner is pregnant or planning to become pregnant during the study.

          -  Recent (within 6 months prior to study drug administration) history of drug or alcohol
             abuse that could preclude adherence to the protocol in the opinion of the
             investigator.

          -  Positive test result at Screening for hepatitis B surface antigen (HBsAg).

          -  HCV genotype performed during screening indicating co-infection with more than one HCV
             genotype.

          -  Chronic HIV type 2 (HIV-2) infection.
      